Overview Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease Status: Completed Trial end date: 2019-08-13 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of oral PRV-6527 in the treatment of moderately to severely active Crohn's disease Phase: Phase 2 Details Lead Sponsor: Provention Bio, Inc.